Health Canada has issued a Notice of Compliance with conditions under the
Notice of Compliance with Conditions (NOC/c) Policy to GlaxoSmithKline Inc., for the drug product, Arzerra™ on the basis of the promising nature of the clinical evidence, and the need for confirmatory studies to verify the clinical benefit. Arzerra™ is indicated for the treatment of patients with chronic lymphocytic leukemia (
CLL) refractory to fludarabine and alemtuzumab. Read the notice of decision
here.